CLINICAL FEATURES, COURSE AND DIAGNOSIS OF GUILLAIN-BARRE SYNDROME

Authors

  • Sabina Zavkiyevna Sattarova
  • Ra'no Bahodirovna Azizova
  • Nargiza Nurmamatovna Abdullaeva
  • Gulnoza Utkurovna Samiyeva

Keywords:

Miller-Fischer syndrome, acute motor axonal neuropathy (AMAN), intravenous immunoglobulin, ganglioside antibodies

Abstract

Guillain-Barre syndrome (GBS) is a very rare autoimmune disease that is associated with demyelination of the peripheral nervous system and progressive muscle weakness that occurs mainly in previously healthy people. The incidence of GBS is 1.1-1.8 cases per 100,000 per year, and the incidence increases with age. The clinical spectrum of GBS is heterogeneous and includes acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), and Miller Fisher Syndrome (MFS). The disease is usually characterized by a rapid onset of symmetrical limb weakness, which progresses within a few days to 4 weeks and occurs in patients of any age. In developed countries, GBS has become the most common cause of acute flaccid paralysis. Despite improved recognition and treatment, GBS continues to be a serious disease.

References

Hughes R.A., Cornblath D.R., Guillain-barre syndrome. The Lancet, 2005; 366(9497): 1653-66.

Govoni V., Granieri E., Epidemiology of the Guillain-Barré syndrome. Current opinion in

neurology, 2001; 14(5): 605-13.

Guillain-Barré Syndrome: Indications for Plasma Exchange. Transfusion Science, 1999; 20: 53–61.

Hughes R.A., Swan A.V., van Doorn P.A., Intravenous immunoglobulin for Guillain‐Barré

syndrome. The Cochrane Library, 2010.

Tsang, R.S. The relationship of Campylobacter jejuni infection and the development of GuillianBarré syndrome. Curr. Opin. Infect. Dis, 2002; 15: 221-228.

Meythaler J.M., Rehabilitation of Guillain-Barré syndrome. Archives of physical medicine and rehabilitation, 1997; 78(8): 872-9.

Raphaël J.C., Chevret S., Hughes R., Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev., 2002; 2(2).

Rees J.H., Soudain S.E., Gregson N.A., Hughes R.A. Campylobacter jejuni infection and Guillain–Barré syndrome. New England Journal of Medicine, 1995; 333(21): 1374-9.

Reilly M., Hutchinson M., Suxamethonium is contraindicated in the Guillain-Barré syndrome. Journal of neurology, neurosurgery, and psychiatry, 1991; 54(11): 1018.

Haymaker WE, Kernohan JW. The Landry-GuillainBarré syndrome; a clinicopathologic report of 50 fatal cases and a critique of the literature. Medicine (Baltimore), 1949; 28(1): 59-141.

Sinhaa S, Prasada KN, Pradhanb S, Jaina D, Jhab S.Detection of preceding Campylobacter jejuni infection by polymerase chain reaction in patients with Guillain-Barré syndrome. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004; 98: 342—346.

McGrogan A., Madle G., SeОМАН H., DeVries C.S. Epidemiology of Guillain-Barré Syndrome worldwide. A systemic literature review. Neuroepidemiology, 2009; 32: 150-63.

Toft CE. Guillian-Barré Syndrome – a case study. Accident and Emergency Nursing, 2002; 10(2): 92- 102.

Parkin RT, Davies-Cole JO, Balbus JM. A definition for chronic sequelae applied to campylobacter and guillian-barre syndrome (СГБ). Annals of Epidemiology, 2000; 10(7): 473.

Brody AJ, Sternbach G, Varon J. Octave landry: Guillain-Barré syndrome. The Journal of Emergency Medicine, 1994; 12(6).

Hahn AF, FRCPC. Guillian-Barre’ syndrome. The Lancet, 1998; 325(9128): 635-641.17. Taylor WA, Brostoff SW, Hughes RAC. P2 specific lymphocyte transformation in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. Journal of the Neurological Sciences, 1991; 104(1): 52-5.

Shahar E, Shorer Z, Roifman CM, Levi Y, Brand N, Ravid S, et al. Immune globulins are effective in severe pediatric Guillain-Barre syndrome. Pediatriс Neurology, 1997; 16(1): 32-6.

Pascuzzi RM, Fleck JD. Acute peripheral neuropathy in adults: Guillain-Barré Syndrome and Related Disorders. Neurologic Clinics, 1997; 15(3): 529-47.

Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain–Barré syndrome. New England Journal of Medicine, 1995; 333(21): 1374-9.

Looney RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Practice & Research Clinical Haematology, 2006; 19(1): 3-25.

Katri B, Koontz D. Disorders of the peripheral nerves. In: Daroff RB, Fenichel GM, Jankovic J,Mazziotta JC, eds. Bradley's Neurology in Clinical Practice. 6th ed. Philadelphia, PA: Elsevier Saunders, 2012; 76.

Hughes R, FMedSci, Cornblath DR. Guillain-Barré syndrome. The Lancet, 2005; 366(9497): 1653–1666.

Kuwabara S. Guillain-Barré Syndrome Epidemiology, Pathophysiology and Management. Drugs, 2004; 64(6): 597-610.

Hughes R, van der Meche FG. Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database Syst Rev., 2000; 2: 001446. 26. Прокоп, Галански. Спиральная и многослойная компьютерная томография (в двух томах), Москва. = 2009. = I том – 413 с. II том. – 710с.

Published

2021-02-26